INJ price eyes $20 as Republic expands RWA with Injective

  • Injective (INJ) price outlook as Republic expands RWA integration with Injective.
  • The INJ token trades around $13.38 after dipping from highs of $16 amid crypto sell-off.
  • ETF anticipation, tokenization growth and other catalysts may help INJ bulls.

Injective price hovers around $13.38 on Thursday evening, about 3% down in the past 24 hours and over 12% down in the past week, but could Injective’s integration with Republic help INJ price bounce to $20?

Over the past week, Injective has dipped from highs of $16, with sell-off pressure across the market adding to the declines.

This is despite the finance-focused layer 1 blockchain’s notable milestones across the ecosystem.

Now with Republic, a leading tokenized investments platform, bulls may fancy higher marks if markets flip bullish.

Injective integrates with Republic

While the crypto market bleeds, platforms are taking time to build.

Integrations are among the critical elements, and Injective has added to this with its official integration with Republic.

The platforms announced the collaboration on Aug. 21 and aim to bring Injective’s Layer 1 ecosystem into Republic’s on-chain investment infrastructure.

Specifically, the goal is to enable Injective-based projects to fundraise via Republic’s Launchpad, utilize Republic Wallet for asset management, and benefit from Republic’s validator support.

Why is this integration notable?

Republic and Injective are building on an earlier collaboration that saw Republic become an INJ validator.

However, and notably, the integration is a step forward in expanding private markets on-chain.

“With 3 million+ community members across 150+ countries and a portfolio that includes 27 unicorns such as SpaceX, Robinhood, Carta, and Dapper Labs, Republic’s integration with Injective represents a pivotal moment in bridging traditional finance with onchain innovation,” Injective wrote.

INJ price outlook: Can bulls reclaim $30?

The technical outlook for INJ is leaning bearish in the short term, with RSI and MACD both handing bears the upper hand.

Currently trading near $13 means the Injective price is closer to the lows of $6.90 seen in April 2025 than the recent peak of $34 hit in December 2024.

The sell-off that has hit Bitcoin and altcoins does not help bulls.

Injective price chart from CoinMarketCap

However, if sentiment flips, a breakout to $20 could allow bulls to target the $30 level.

Other than the Republic integration, other significant upward drivers will be overall institutional interest and demand amid tokenization and real-world assets.

Injective’s quest to dominate with new financial primitives designed to expand its DeFi capabilities, and the Nvidia GPU derivatives market add to the positives.

Also bullish for Injective price is anticipation around ETF filings and expected approvals and whale accumulation will be key.

Bulls nonetheless need to hold above $13 and potentially $10 so as not to hand greater initiative to bears.

The post INJ price eyes $20 as Republic expands RWA with Injective appeared first on CoinJournal.

Show original
1.56K
0
The content on this page is provided by third parties. Unless otherwise stated, OKX is not the author of the cited article(s) and does not claim any copyright in the materials. The content is provided for informational purposes only and does not represent the views of OKX. It is not intended to be an endorsement of any kind and should not be considered investment advice or a solicitation to buy or sell digital assets. To the extent generative AI is utilized to provide summaries or other information, such AI generated content may be inaccurate or inconsistent. Please read the linked article for more details and information. OKX is not responsible for content hosted on third party sites. Digital asset holdings, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition.